New York Life Investment Management LLC Buys 4,219 Shares of Bristol-Myers Squibb (NYSE:BMY)

New York Life Investment Management LLC raised its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 1.4% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 315,523 shares of the biopharmaceutical company’s stock after purchasing an additional 4,219 shares during the period. New York Life Investment Management LLC’s holdings in Bristol-Myers Squibb were worth $17,846,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Lineweaver Wealth Advisors LLC bought a new stake in Bristol-Myers Squibb during the fourth quarter valued at about $1,165,000. Nwam LLC lifted its position in shares of Bristol-Myers Squibb by 3.1% in the fourth quarter. Nwam LLC now owns 18,473 shares of the biopharmaceutical company’s stock valued at $1,045,000 after acquiring an additional 551 shares in the last quarter. NewEdge Wealth LLC lifted its position in shares of Bristol-Myers Squibb by 23.7% in the fourth quarter. NewEdge Wealth LLC now owns 26,443 shares of the biopharmaceutical company’s stock valued at $1,496,000 after acquiring an additional 5,073 shares in the last quarter. Whipplewood Advisors LLC purchased a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at about $82,000. Finally, Oregon Public Employees Retirement Fund lifted its position in shares of Bristol-Myers Squibb by 0.3% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 173,899 shares of the biopharmaceutical company’s stock valued at $9,836,000 after acquiring an additional 450 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

BMY has been the topic of several research analyst reports. Morgan Stanley boosted their price objective on Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an “underweight” rating in a research report on Tuesday, November 12th. Bank of America restated a “neutral” rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Daiwa America upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 13th. Wolfe Research initiated coverage on Bristol-Myers Squibb in a research report on Friday, November 15th. They issued a “peer perform” rating on the stock. Finally, Wells Fargo & Company boosted their price objective on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “equal weight” rating in a research report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, four have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $57.86.

Insider Activity

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 1,823 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were purchased at an average price of $54.84 per share, with a total value of $99,973.32. Following the completion of the purchase, the executive vice president now owns 63,932 shares in the company, valued at $3,506,030.88. This represents a 2.94 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Trading Down 1.5 %

Shares of BMY stock opened at $57.34 on Thursday. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $61.10. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The stock’s 50 day simple moving average is $57.06 and its two-hundred day simple moving average is $54.58. The company has a market cap of $116.35 billion, a PE ratio of -12.97, a price-to-earnings-growth ratio of 2.07 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Research analysts predict that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were paid a dividend of $0.62 per share. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date of this dividend was Friday, January 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.33%. Bristol-Myers Squibb’s dividend payout ratio is currently -56.11%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.